{"entity":{"id":"psmb9","kind":"target","name":"PSMB9","aka":["proteasome 20S subunit beta 9","Proteasome subunit beta type-9","RING12","beta1i","PSMB6i","LMP2"],"tldr":"PSMB9 (Proteasome subunit beta type-9) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","summary":"The proteasome is a multicatalytic proteinase complex which is characterised by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides.\n\nOpen Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.00, clinical 0.99).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:9546","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9546"},{"label":"UniProt P28065","url":"https://www.uniprot.org/uniprotkb/P28065/entry"},{"label":"NCBI Gene 5698","url":"https://www.ncbi.nlm.nih.gov/gene/5698"},{"label":"Ensembl ENSG00000240065","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000240065"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["multiple-myeloma","non-hodgkin-lymphoma","mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"PSMB9","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:9546","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9546","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P28065","url":"https://www.uniprot.org/uniprotkb/P28065/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000240065","url":"https://platform.opentargets.org/target/ENSG00000240065/associations","note":"association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: plasma cell myeloma 0.61, non-Hodgkin lymphoma 0.57, mantle cell lymphoma 0.54 (GraphQL API, CC0)"}],"distribution":"few-types","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA PSMB9: RNA tissue enhanced (lymphoid tissue 140 nTPM); no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (plasma cell myeloma, mantle cell lymphoma). (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas PSMB9 tissue","url":"https://www.proteinatlas.org/ENSG00000240065-PSMB9/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000240065 associations","url":"https://platform.opentargets.org/target/ENSG00000240065/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:9546","ensembl":"ENSG00000240065","uniprot":"P28065","entrez":"5698","firstDescribed":1991,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Kelly et al, Nature, 1991, \"Second proteasome-related gene in the human MHC class II region\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/1922385/","biology":"The proteasome is a multicatalytic proteinase complex which is characterised by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB6 by PSMB9 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Location: Cytoplasm; Nucleus (UniProt). Locus 6p21.32 (HGNC).","whereFound":["Multiple myeloma: Open Targets association 0.61 with plasma cell myeloma (MONDO_0009693)","Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908)","Mantle cell lymphoma: Open Targets association 0.54 with mantle cell lymphoma (MONDO_0018876)"],"targetClass":"enzyme","prevalence":[]},"route":"/targets/psmb9/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}